Leukemia Research
Volume 30, Issue 4 , Pages 385-388 , April 2006

Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes

References 

  1. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients fron 17 studies. Br J Haematol. 1995;89:67–71
  2. Italian Cooperative Study Group for r-Hu-Epo in Myelodysplastic Syndromes.. A randomized, double-blind, placebo-controlled study with subcutaneous human erythropoietin in patients with low risk myelodysplastic syndromes. Br J Haematol. 1998;103:1070–1074
  3. Musto P, Falcone A, Sanpaolo G, Bodenizza C, La Sala A, Perla G, et al. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol. 2003;122:269–271
  4. Aloe-Spiriti MA, Latagliata R, Niscola P, Cortelezzi A, Francescani M, Ferrari D, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol. 2005;84:167–176
  5. Raza A, Mayer P, Dutt D, Zorat F, Lisak L, Nascimben F, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001;98:958–965
  6. Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide in the treatment of patients with myelodysplastic syndromes. Leukemia. 2002;16:1–6
  7. Musto P, Falcone A, Sanpaolo G, Bisceglia M, Matera R, Carella AM. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Haematologica. 2002;87:884–886
  8. Bowen D, Mac Ilwaine L, Cavanagh J, Killick S, Culligan D, Thomson E, et al. Thalidomide therapy for low-risk myelodysplasia. Leuk Res. 2005;29:235–236
  9. Hellstrom-Lindberg E. Approach to anemia of myelodysplastic syndromes. Curr Hematol Rep. 2003;2:122–129
  10. Musto P. Revisiting the use of recombinant erythropoietin in myelodysplastic syndromes. Clin Lymphoma. 2005;6:2–5
  11. Musto P. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res. 2004;28:325–332
  12. Greenberg PL, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis of myelodysplastic syndromes. Blood. 1997;89:2079–2088
  13. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–3849
  14. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. World Health Organization (WHO) International Working Group. Report of an International Working Group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671–3674
  15. Stasi R, Brunetti M, Terzoli E, Amadori S. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood. 2002;99:578–584
  16. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120:1037–1046
  17. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood. 1996;87:4076–4081
  18. Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarre MC, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood. 2004;104:321–327
  19. Musto P, Sanpaolo G, D’Arena G, Scalzulli P, Matera R, Falcone A, et al. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Haematologica. 2001;86:44–51
  20. Grossi A, Musto P, Santini V, Balestri F, Fabbri A, Falcone A, et al. Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. Haematologica. 2002;87:322–323
  21. Tefferi A, Elliot MA, Steensma DP, Hook CC, Dispenzieri A, Hanson CA, et al. Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndromes. Leuk Res. 2001;25:1853–1855
  22. Candoni A, Raza A, Silvestri F, Lisak L, Galili N, Mumtaz M, et al. Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes. Ann Hematol. 2005;84:479–481
  23. Raza A, Buonamici S, Lisak L, Tahir S, Li D, Imran M, et al. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res. 2004;28:791–803
  24. Steurer M, Sudmeier I, Stauder R, Gastl G. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol. 2003;121:101–103

PII: S0145-2126(05)00330-9

doi: 10.1016/j.leukres.2005.08.020

Leukemia Research
Volume 30, Issue 4 , Pages 385-388 , April 2006

Article Tools

* Image Usage & Resolution